Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label trial of insulin peglispro vs insulin glargine in Asian insulin-naive adults with type 2 diabetes mellitus
jRCT2080222150Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin peglispro in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Started Jul 2013; status: recruiting.
02
Drugs
insulin peglispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080222150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222150.